This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This flyer is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging parents to talk with their kids about opioids.

This wallet card is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging military parents to talk with their kids about opioids.

This wallet card is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging parents to talk with their kids about opioids.

This infographic is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign for parents on the risks of opioids and why they should start talking with their kids about the facts.

This brochure is related to the public service announcement from SAMHSA's “Talk. They Hear You.” campaign encouraging parents to talk with their kids about the risks of misusing prescription pain medications and to have conversations with their kids to help them avoid taking medication that is not theirs.